Clinical Trials

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Phase 1/2 Completed

97 enrolled 43 charts

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06697184 2025-12-17

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

56 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

40 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04172246 2025-11-21

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Phase 1/2 Completed

55 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06029309 2025-10-06

ZANU-TAFA

27 enrolled

Lymphoma, Mantle-Cell

NCT06375733 2025-08-12

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

51 enrolled

385 enrolled 29 charts 2 FDA

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02343120 2022-04-28

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Phase 1/2 Completed